Sunlight avoidance and cancer prevention in xeroderma pigmentosum

Non‐invasive management of non‐melanoma skin cancer in patients with cancer predisposition genodermatosis: a role for confocal microscopy and photodynamic therapy

“…In XP, dermoscopy allowed a more detailed preoperative evaluation of the tumours, aiding decisions regarding biopsy and excision in a study by Malvehy et al. 11 …”

“…Patients with XP usually develop a great number of skin tumours at an early age such as basal cell carcinoma (BCC) and squamous cell carcinoma, actinic keratosis (AK), atypical moles and malignant melanoma associated with severe photoageing 10 . The prognosis in these cases depends on strict UV photoprotection, 11 and the early diagnosis and surgical treatment of skin tumours. The clinical diagnosis of skin tumours at an early stage and the discrimination between malignant lesions and benign lesions is challenging in these patients because of the presence of severe UV‐induced skin damage with the generalized presence of actinic lentigines, AKs and poikiloderma.…”

Dermoscopy of skin lesions in two patients with xeroderma pigmentosum

“…Patients with XP usually develop a great number of skin tumours at an early age such as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), actinic keratosis (AK), atypical moles and malignant melanoma (MM) associated with severe photoageing. 3 The prognosis in these cases depends on strict UV photoprotection, 4 a strict clinical follow-up, and the early diagnosis and surgical treatment of skin tumours. Unfortunately, the clinical diagnosis of skin tumours at an early stage and the discrimination between malignant lesions and benign lesions is not easy in these patients because of the presence of severe UV-induced skin damage with the generalized presence of actinic lentigos, AKs and poikiloderma.…”

Total-Body Cutaneous Examination, Total-Body Photography, and Dermoscopy in the Care of a Patient With Xeroderma Pigmentosum and Multiple Melanomas

“…6 Sun protection and avoidance are the means of primary skin cancer prevention in this group of patients. 7 The median interval between the onset of XP symptoms to the first neoplasm is 5 years, and almost 50% of patients with XP will develop skin cancer by age 8 years. 8 The diagnosis of cutaneous melanoma in patients with XP is often difficult because of severe actinic damage, which includes telangiectasias, atrophy, hyperkeratosis, and extensive poikilodermatous changes that occur in sunexposed areas.…”